Identify Patients at Risk of Cognitive Decline

0 reactions
0 comments
Video Thumbnail

$1.99

Play Button
We would love to hear your thoughts.
Join the discussion below
Summary

This speaker presentation features Heather Sandison, ND, and Dr. Richard Pither discussing a new test that can help practitioners identify patients at risk of cognitive decline, specifically those at risk of developing Alzheimer’s disease. The test uses genetic mapping to produce a polygenic risk score, categorizing individuals into risk groups. It is less invasive and expensive than other techniques and is readily available to everyone.

Cytox launched their test, “The Alzheimer’s Risk Test – powered by genoSCORE,” in North America in late 2021, led by their testing laboratory partner, Sampled – The Alzheimer’s Risk Test is a Polygenic Risk Scoring (PRS) test that provides a comprehensive assessment of genetic risk linked to late-onset Alzheimer’s disease and associated cognitive decline. Alzheimer’s disease is a highly complex disease with risk factors based on genetics, lifestyle, age, and environment, but up to 50% of the risk factors are modifiable and so can be addressed to reduce overall risk.

The Alzheimer’s Risk Test is offered by approved clinical practices and requires only a simple saliva sample; it uses a Polygenic Risk algorithm to predict the risk of individuals developing Alzheimer’s disease and optimize clinical management of those at the highest risk. While the test is not a diagnostic tool, it can provide individuals with valuable information to take proactive measures to mitigate their overall risk. This test is specifically designed to identify individuals at risk of Alzheimer’s disease and falls into two categories: symptomatic individuals and younger individuals with a family history of cognitive decline.

It is essential to seek professional clinical support before taking the test as genetic input, environmental factors, and comorbidities all contribute to overall Alzheimer’s risk.

Takeaways:

  • A groundbreaking test can identify individuals at risk of Alzheimer’s disease and cognitive decline.
  • The test is conducted through a genetic mapping exercise, producing a single number describing an individual’s genetic risk.
  • The test is readily available to everyone and requires either a saliva collection kit or a blood sample, and it is less invasive and far less expensive than other techniques.
  • While knowing one’s Alzheimer’s risk can be significant, it is essential to remember that genetic input, environmental factors, and comorbidities contribute to overall Alzheimer’s risk.
  • Patients should discuss the test with their clinician to determine whether it suits them and seek professional clinical support before taking it. A proactive approach to managing lifestyle and environmental risks is crucial for everyone.
Transcript
Heather Sandison, N.D.

Welcome back to the Reverse Alzheimer’s Summit. I’m your host, Dr. Heather Sandison, and I’m delighted to introduce you to Dr. Richard Pither. He’s the CEO of Cytox. At Cytox, Richard has spent 25 years in the Alzheimer’s disease field and is focused on developing novel genetic tests for assessing Alzheimer’s disease risk. The genoSCORE test, developed in partnership with Thermo Fisher Scientific and Sampled, is aimed at clinicians assessing patients at risk of cognitive decline due to Alzheimer’s disease, in addition to pharma companies seeking high-risk patients for recruitment into clinical trials. Over the past 25 years, Richard has developed diagnostic and therapeutic products for GE, UCB, Caltech, Laurantis, and Amersham. Richard’s academic training is from Bristol University in the UK and Harvard Medical School. Richard, thanks so much for taking the time to join us.

Join the discussion

or to comment

Related Videos

Reverse Alz Featured Image – Cheng-Huai Ruan, MD

What Your Skull Reveals About Your Brain Health

Cheng Ruan, MD
Reverse-Alz-Featured-Image-David-Haase

Root Cause: Impacting Brain Function

David Haase, MD
Reverse-Alz-Featured-Image-Dr-heather-Presentation

Mental Health and Dementia

Heather Sandison, ND
Reverse Alz Featured Image – Sally Weinrich

Interview with a First Survivor of Alzheimer’s.

Dr. Sally Weinrich
Reverse Alz Featured Image – Kara Fitzgerald

Younger You – Aging is Optional

Kara Fitzgerald, ND, IFMCP
Reverse Alz Featured Image – Matt Cook

Peptides as a tool for Reversing Dementia

Matt Cook, MD

drtalks_logo

Single Video Purchase

Identify Patients at Risk of Cognitive Decline

Buy Now - $1.99

Or Access Unlimited Videos from our Library when you subscribe to our Premium membership

Premium Membership

Unlimited Video Access

$19/month    or    $197/year

Go Premium
drtalks logo

SMS number

Login to DrTalks using your phone number

✓ Valid
Didn't receive the SMS code? Resend
drtalks_logo.png

Create an Account

or

Signup with email

Already have an account? Log In

DrTalks comes with great perks that guests to our site don’t have access to. Sign up for FREE

drtalks_logo

Become a member

DrTalks comes with great perks that guests to our site don’t have access to. Sign up for FREE

"*" indicates required fields

Name*
Password*

Already have an account? Log In

drtalks_logo.png

Sign-in

Login to get access to DrTalks wide selection of expert videos, your summit or video purchases.

or